Synthesis and Antimicrobial Evaluation of New 1,2,4-Triazolo[1,5-a]pyrimidine-Based Derivatives as Dual Inhibitors of Bacterial DNA Gyrase and DHFR
Open Access
- 11 November 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (47) , 47261-47273
Abstract
A series of 1,2,4-triazolo[1,5-a]pyrimidine-based derivatives were developed and prepared by reacting chalcones 8a-p with 3-phenyl-1,2,4-triazole-5-amine (5). The novel compounds were analyzed using several spectroscopic techniques, and their antimicrobial efficacies against six pathogens (Gram-negative, Gram-positive, and fungi) were tested. Most of the tested compounds exhibited significant antimicrobial activity compared to ciprofloxacin and fluconazole. Four compounds (9d, 9n, 9o, and 9p) showed promising results. Their minimal inhibitory concentration (MIC) values were between 16 and 102 mu M, similar to ciprofloxacin's 10-90 mu M values. MIC values against the tested fungal species were between 15.50 and 26.30 mu M, higher than fluconazole's 11.50-17.50 mu M values. Compounds 9n and 9o, in particular, showed excellent bactericidal activity. Compounds 9n and 9o, the most effective antibacterial agents, were further evaluated for their inhibitory effects on bacterial DNA gyrase and DHFR enzymes as possible molecular targets. The results indicated that 9n and 9o demonstrated a similar level of activity against DNA gyrase and DHFR when compared to the reference drugs ciprofloxacin and trimethoprim. We conducted molecular docking to investigate the binding mechanism and evaluate the reactivity of the intriguing compounds. Compounds 9n and 9o demonstrated favorable binding interactions with the essential amino acids necessary for the inhibition of E. coli DNA gyrase and DHFR enzymes.Keywords
Funding Information
- Karlsruhe Institute of Technology
- Princess Nourah Bint Abdulrahman University (PNURSP2023R3)
This publication has 46 references indexed in Scilit:
- Folate Biosynthesis Pathway: Mechanisms and Insights into Drug Design for Infectious DiseasesFuture Medicinal Chemistry, 2018
- Synthesis and Evaluation of N‐Phenylpyrrolamides as DNA Gyrase B InhibitorsChemMedChem, 2018
- Dihydrofolate Reductase As A Therapeutic Target for Infectious Diseases: Opportunities And ChallengesFuture Medicinal Chemistry, 2012
- Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum programDiagnostic Microbiology and Infectious Disease, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Essramycin: A First Triazolopyrimidine Antibiotic Isolated from Nature†The Journal of Antibiotics, 2008
- Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substancesNature Protocols, 2008
- Chapter 9 Regulation of Human Dihydrofolate Reductase Activity and Expression2008
- The interaction between coumarin drugs and DNA gyraseMolecular Microbiology, 1993
- Dihydrofolate reductase as a therapeutic targetThe FASEB Journal, 1990